Differences in time till phlebitis onset in patients injected with ancaron injection or amiodarone hydrochloride injection 150mg “TE”

DOI Web Site
  • SAITO Masayuki
    Department of Pharmacy, Tosei General Hospital Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University
  • NAKASHIMA Yoshihito
    Department of Emergency Medicine, Tosei General Hospital
  • HORI Eisei
    Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University
  • SUZUKI Tadashi
    Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University
  • ICHIHARA Toshihiko
    Department of Emergency Medicine, Tosei General Hospital

Bibliographic Information

Other Title
  • アンカロン注とアミオダロン塩酸塩注150mg“TE”を注射した患者における静脈炎発症までの時間の違い

Search this article

Abstract

<p>Amiodarone is widely used to treat life-threatening arrhythmias in adults. This study included 314 patients who received amiodarone intravenously via a peripheral vein at our hospital from January 2008 to December 2021. Of these, 40 (12.7%) patients developed phlebitis. We compared the time from the administration of branded versus generic amiodarone to the onset of phlebitis. The results revealed that the time to phlebitis onset was shorter with generic amiodarone than the branded equivalent (p<0.001). The generic group also exhibited a higher increase in the white blood cell ratio from the start of administration to the onset of phlebitis than the branded group (p=0.04). These results suggest potential dangers associated with the use of generic amiodarone. Information available on the safety of generic intravenous medicines is limited, and further research is warranted to identify the causes of the differences observed in this study. </p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top